The US Food and Drug Administration (FDA) has approved Hympavzi (marstacimab, Pfizer) as routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years or older ...

On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...

Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors.

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved HYMPAVZI™ for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.

(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...